Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

IRIX vs CPIX: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

CPIX Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 7–3 Matrix Metrics)

CPIX Overall Winner 6-Pillar Tally: IRIX 2 – 4 CPIX Matrix Metrics: IRIX 3 – 7 CPIX

As of Nov 16, 2026, Cumberland Pharmaceuticals Inc (CPIX) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IRIX carries a Unified Composite Score of 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin), whereas CPIX carries 49.1/100 (HOLD) at $5.21 (50.0x Forward P/E, -4.7% operating margin).

  • Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. CPIX 49.1/100 HOLD), CPIX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. -5.4% operating margin) and revenue trajectory (-74.0% vs. -7.4% YoY).
  • Technical & Structure Timing Caution: IRIX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2); meanwhile CPIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About IRIX vs CPIX
IRIX NASDAQ
Iridex Corp
Electromedical & Electrotherapeutic Apparatus
$0.69
-0.32% 1D
Market Cap $12.1M
TTM Revenue $52M
Forward P/E N/M
Beta / 30D Vol 0.66β · 58% Vol
Unified Composite Score
51.8 / 100 HOLD
Tech 52.0 Fund 65.0 Flow 50.0 Mom 50.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 45
RSI-14: 45.2 · SMA20: $0.72 · SMA50: $0.71
CPIX NASDAQ Head-to-Head Winner
Cumberland Pharmaceuticals Inc
Pharmaceutical Preparations
$5.21
-11.39% 1D
Market Cap $88.2M
TTM Revenue $46M
Forward P/E 50.0x
Beta / 30D Vol 0.44β · 222% Vol
Unified Composite Score
49.1 / 100 HOLD
Tech 40.0 Fund 63.0 Flow 72.0 Mom 50.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -10.7%), weak momentum, RSI 44
RSI-14: 44.1 · SMA20: $5.70 · SMA50: $6.61

6-Pillar Scorecard Institutional Category Breakdown (IRIX 2 – 4 CPIX)

Columns: Metric · IRIX · CPIX
1. Valuation Multiples CPIX
Forward P/E N/M 50.0x
Trailing P/E N/M 50.0x
PEG Ratio 0.94x 1.67x
EV / Revenue 0.2x 1.9x
2. Growth & Scale IRIX
Revenue Growth (YoY) -7.4% -74.0%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $52M $46M
Market Cap $12.1M $88.2M
3. Profitability & Quality CPIX
Gross Margin 35.9% 83.3%
Operating Margin -5.4% -4.7%
Net Profit Margin -6.9% 148.6%
Return on Equity (ROE) -73.2% -3.4%
4. Balance Sheet & Cash Flow CPIX
Cash Generation (TTM) -$2.5M $2.0M EBITDA
Cash Flow Margin -4.9% 4.3% EBITDA Mgn
Net Cash / Leverage -$319,000 Net Debt (0.90x D/E) $4.84 Book/Sh · -3.4% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning CPIX
Options Structure Phase UNCLASSIFIED BREAKDOWN
Current IV / %ile N/A (N/A) 296.2% (37th %ile)
Put/Call OI Skew N/A 0.02x (Call-Skewed)
OBV Trend / Tech Phase NEUTRAL · Neutral NEUTRAL · Markdown
6. R&D & Supply-Chain Moat IRIX
OpEx & R&D Intensity 41.3% of Rev ($21M) N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Drug Manufacturers - Specialty & Generic Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: IRIX (3) vs CPIX (7)
Institutional Metric IRIX CPIX Criterion Row Edge
Market Capitalization
Scale
$12.1M $88.2M Larger Scale CPIX
Trailing P/E Ratio
Valuation
N/M 50.0x Lower Multiple CPIX
Forward P/E Ratio
Valuation
N/M 50.0x Lower Multiple CPIX
Revenue Growth (YoY)
Growth
-7.4% -74.0% Higher Growth IRIX
Operating Margin (TTM)
Profitability
-5.4% -4.7% Higher Margin CPIX
Net Profit Margin
Profitability
-6.9% 148.6% Higher Margin CPIX
Return on Equity (ROE)
Capital Efficiency
-73.2% -3.4% Higher ROE CPIX
52-Week Range Position
Momentum
8% ($1–$2) 45% ($2–$9) Stronger Trend CPIX
Beta / 30D Volatility
Risk Regime
0.66β · 58% Vol 0.44β · 222% Vol Lower Realized Risk IRIX
Unified Institutional Score
Composite Signal
51.8 / 100 (HOLD) 49.1 / 100 (HOLD) Higher Composite IRIX
Trailing 12M Revenue (USD)
Operating Scale
$52M $46M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
35.9% 83.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.94x PEG · 0.2x EV/Rev 1.67x PEG · 1.9x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$2.5M (-$319,000 Net Debt (0.90x D/E)) $2.0M EBITDA ($4.84 Book/Sh · -3.4% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon IRIX +11.87 pp
IRIX: -15.57% · CPIX: -27.44%
3M Horizon IRIX +5.67 pp
IRIX: -26.05% · CPIX: -31.72%
6M Horizon CPIX +34.0 pp
IRIX: -32.24% · CPIX: +1.76%
1Y Horizon CPIX +171.77 pp
IRIX: -22.49% · CPIX: +149.28%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period IRIX Revenue CPIX Revenue IRIX Op. Margin CPIX Op. Margin Margin Leader
FY2019 $40M $30M -20.7% -28.7% IRIX
FY2020 N/A $40M N/A -17.8% CPIX
FY2021 $40M $40M -18.1% -21.9% IRIX
FY2022 $60M $40M -13.2% -13.6% IRIX
FY2023 $50M $40M -19.3% -24.2% IRIX
FY2024 $50M $40M -17.1% -17.0% CPIX
FY2025 N/A $40M N/A -6.3% CPIX
FY2026 $50M N/A -4.9% N/A IRIX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
IRIX UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact IRIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
CPIX BREAKDOWN
87d in phase · OBV NEUTRAL
Current IV 296.2%
IV Percentile 37th %ile
Put/Call OI Skew 0.02x (Call-Skewed)
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow NEUTRAL
Exact CPIX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
IRIX Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $12.1M market capitalization and -5.4% operating margin.
OpEx & R&D Reinvestment 41.3% of Rev ($21M)
90D Engineering Disclosures 0 Published
CPIX Moat Profile Cyclical / Execution-Driven Positioning
Drug Manufacturers - Specialty & Generic Operator
Competes within the Drug Manufacturers - Specialty & Generic value chain with $88.2M market capitalization and -4.7% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ IRIX vs CPIX Key Questions & Quantitative Answers

As of Nov 16, 2026, Cumberland Pharmaceuticals Inc (CPIX) is the stronger overall head-to-head candidate over Iridex Corp (IRIX) in the Tradestie Institutional Equity Comparison Engine, winning 7–3 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Profitability & Quality, Balance Sheet & Cash Flow). IRIX carries a Unified Composite Score of 51.8/100 (HOLD) at $0.69 (N/M Forward P/E, -5.4% operating margin), whereas CPIX carries 49.1/100 (HOLD) at $5.21 (50.0x Forward P/E, -4.7% operating margin). Composite vs. Pillar Nuance: While IRIX currently prints a higher short-term Unified Composite Score (51.8/100 HOLD vs. CPIX 49.1/100 HOLD), CPIX captures the overall institutional head-to-head verdict (7–3 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-4.7% vs. -5.4% operating margin) and revenue trajectory (-74.0% vs. -7.4% YoY). Technical & Structure Timing Caution: IRIX trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 45.2); meanwhile CPIX is in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 44.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

IRIX leads the Growth & Scale pillar: IRIX posts -7.4% YoY revenue growth and +0.0% YoY earnings growth on $52M TTM revenue (35.9% gross margin, -5.4% operating margin), compared with CPIX at -74.0% YoY revenue growth and +0.0% YoY earnings growth on $46M TTM revenue (83.3% gross margin, -4.7% operating margin). Across the 8-period historical trajectory (FY2019 to FY2026), IRIX cumulative revenue shifted +25.0% while CPIX shifted +33.3%. In operating R&D and SG&A reinvestment, IRIX deploys 41.3% of Rev ($21M) (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for CPIX.

CPIX screens cheaper on headline valuation multiples. IRIX trades at N/M Forward P/E, N/M Trailing P/E, 0.94x PEG, and 0.2x EV/Revenue (-4.9% FCF margin), whereas CPIX trades at 50.0x Forward P/E, 50.0x Trailing P/E, 1.67x PEG, and 1.9x EV/Revenue (4.3% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against IRIX (-73.2% ROE) versus CPIX (-3.4% ROE) capital efficiency.

In options market volatility and institutional positioning, IRIX carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.66β · 58% Vol realized risk). By comparison, CPIX carries 296.2% implied volatility (37th %ile, Balanced (25th–60th %ile)), a 0.02x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKDOWN options structure phase (0.44β · 222% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.